Figure 2.

The future of NAFLD management. NAFLD patients will be divided into different disease stages and managed in a similar fashion to the current management of individuals within the type 2 diabetes spectrum. OCA, obeticholic acid; CVC, cenicriviroc; SEL, selonsertib; CAD, coronary artery disease; CKD, chronic kidney disease; HCC, hepatocellular carcinoma; EV, esophageal varices; NAFLD, nonalcoholic fatty liver disease;